Clinical Significance of 22C3-PD-L1 IHC Expression in Surgically Resected Non-Small Cell Lung Cancer
Gen Lin,Chao Li,Cheng Huang,Rong Xi Fang,Peng Hai Xu,Dong xian Lin,Biao Wu,Xiaohui Chen,Chunwei Xu,Tony Mok
DOI: https://doi.org/10.1200/jco.2017.35.15_suppl.e20507
IF: 45.3
2017-01-01
Journal of Clinical Oncology
Abstract:e20507 Background: Multiple studies correlated PD-L1 expression with clinicopathologic and survival have reported conflicting results.Methods: We retrospectively collected 185 patients with NSCLC who underwent surgical resection to detect PD-L1 IHC using the clone 22C3 pharmDx kit and evaluated PD-L1 expression along with clinicalpathological characteristics and prognosis.Results: Most of tumors had TNM stage lower than stage III. Adenocarcinoma and squamous carcinoma was accounting for 56.8% and 43.2%, respectively. Heterogeneous distribution of PD-L1 staining was observed, PD-L1 strong-positive and weak-positive staining were detected in 11.4% and 24.3% of patients. In univariate analysis, smokers, squamous carcinoma, central type cancer, larger primary tumor size, metastatic lymphonode, neoadjuvant chemotherapy and TILs present was found associations with higher proportion of PD-L1 positive expression. In multivariate analysis, only primary tumor size, smoking status, TILs status and neoadjuvant chemotherapy were confirmed associations with PD-L1 positive expression. Especially, PD-L1 positive expression rate climbed gradually with the increase of tumor size, T≤3cm 21.0%, 3cm < T≤5cm 32.8%, 5cm < T 50.7%, respectively, p = 0.003. PD-L1 positive expression highly improved with patients with neoadjuvant chemotherapy versus without neoadjuvant chemotherapy, 88.9% vs 33.0%, respectively, p = 0.009. In survival analysis, neither PD-L1 expession/TILs status nor the interaction term between were confirmed as independent prognosis biomarkers . PD-L1 negative group had a tendency of longer OS than PD-L1 positive group, mOS 66.4 months (95%CI, 59.4-73.4) vs. 39.2 months (95%CI, 16.0-62.4), respectively, p = 0.096. Conclusions: PD-L1 expression showed heterogeneous distribution and was highly influenced by tumor size, smoking status, TILs and neoadjuvant chemotherapy.It indicated a strong spatial and temporal variability in the PD-L1 expression, which could be in part to explain the conflicting results in PD-L1 expression and correlation with clinicopathologic in multiple studies. The dynamics of PD-L1 expression may also limit its use as a prognosis biomarker.